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Triterpene saponosides are widely distributed plant sec-
ondary metabolites characterized by relatively low sys-
temic cytotoxicity and a range of biological activities. 
These include anti-inflammatory, antimicrobial, vasopro-
tective and antitumor properties. In particular, the ability 
of saponins to enhance the cytotoxicity of chemothera-
peutic drugs opened perspectives for their application in 
combined cancer chemotherapy. Here, we used human 
prostate cancer DU-145 cells as an in vitro model to elu-
cidate the synergy of the interactions between biological 
activities of an oleanane type 13β,28-epoxy triterpene 
saponoside (Lclet 4) and mitoxantrone, which is a cyto-
static drug commonly used in prostate cancer therapy. 
No cytotoxic or pro-apoptotic effect of Lclet 4 and mi-
toxantrone administered at the concentrations between 
0.05 and 0.1 µg/ml could be seen. In contrast, cocktails 
of these agents exerted synergistic pro-apoptotic ef-
fects, accompanied by the activation of the caspase 3/7 
system. This effect was paralleled by attenuating effects 
of Lclet 4/mitoxantrone cocktails on the invasive poten-
tial, metalloproteinase expression and motility of DU-
145 cells. Multifaceted and additive effects of Lclet 4 and 
mitoxantrone on basic cellular traits crucial for prostate 
cancer progression indicate that the combined applica-
tion of both agents at systemically neutral concentra-
tions may provide the basis for new promising strategies 
of prostate cancer chemotherapy.
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INTRODUCTION
Prostate cancer is one of the most commonly diag-
nosed tumors in men and the second leading cause of 
cancer mortality in Europe and USA (Arcangeli et al., 
2012). At early stages, it can be treated with surgery and 
androgen deprivation therapy, but no efficient curative 
therapy exists against its progressed, hormone refrac-
tory and malignant form (Crawford & Connor, 2009). 
Moreover, currently available therapeutical approaches 
evoke a number of adverse effects, which increase the 
morbidity and mortality rates of the patients (Ichikava et 
al., 2005; Hurria et al., 2011). For instance, this problem 
concerns the application of mitoxantrone, a widely used 
cytostatic and anti- neoplastic drug (Bouchet et al., 2010). 
Elderly patients treated with mitoxantrone-based therapy 
usually suffer from acute and/or delayed bone marrow 
depression, cardiomyopathy and mucositis (Fleming et 
al., 2012), which considerably limit its benefits.
A promising possibility of reducing the adverse effects 
of prostate cancer chemotherapy without attenuation of 
its efficiency is provided by a combined application of 
chemotherapeutic agents and plant phytochemicals char-
acterized by anti-cancer activity, such as saponosides 
(Kim et al., 2010). Till recently, saponosides were pre-
dominantly used as adjuvants that enhance the effect of 
vaccines (Liu et al., 2012). In cancer therapy, they were 
applied in combination with immunotoxins to increase 
the selectivity of the immunotoxin against cancer cells 
and to inure normal cells to its cytotoxic effect (Weng et 
al., 2012). On the other hand, direct pro-apoptotic, anti-
angiogenic, cytostatic and anti-invasive activity of sapon-
osides has been demonstrated (Galanty et al., 2008; Chen 
et al., 2012; Kim et al., 2012; Podolak et al., 2013). They 
can enhance the effect of commonly used chemothera-
peutic agents, suggesting possibilites for lowering their 
therapeutic doses and reducing the possible side-effects 
of chemotherapy The observations of therapeutic effi-
cacy of the combinations of some natural products from 
Traditional Chinese Medicine with standard chemothera-
peutic agents (Efferth et al., 2002; Hofman et al., 2012) 
warrant intensive research on the anti-cancer activity of 
saponosides and on the mechanisms of their interference 
with chemotherapeutics.
In vitro models of prostate cancer were previously ap-
plied to identify the determinants of prostate cancer in-
vasion (Djamgoz et al., 2001, Miękus et al., 2005). They 
also facilitate the elucidation of pro-apoptotic and anti-
invasive activities of phytochemicals in strictly controlled 
conditions (Czernik et al., 2008 Wybieralska et al.,2011; 
Gawlik-Dziki et al., 2012, Gawlik-Dziki et al., 2013). In 
the present study, we investigated the synergy of pro-
apoptotic and anti-invasive effects of a newly identi-
fied triterpene saponoside (referred to as Lclet 4) and 
mitoxantrone (MTX) in human prostate DU145 cell 
populations. Lclet 4 is an oleanane type 13β,28-epoxy 
triterpene saponoside isolated from Lysimachia clethroides 
(Duby), which contains a branched sugar chain (3-O-β-
D-glucopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→2)-
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β-D-glucopyranosyl-(1→4)-]-α-L-arabinopyranosyl-pro-
toprimulagenin A). Our preliminary studies have shown 
a prostate cancer cell-specific pro-apoptotic effect of 
Lclet 4 (unpublished data). In the present study, we 
demonstrate that it can dramatically reduce the therapeu-
tic doses of MTX in prostate cancer treatment.
MATERIALS AND METHODS
Plant material and Lclet 4 isolation. Underground 
parts of Lysimachia clethroides (Duby) were collected from 
The Garden of Medicinal Plants, Jagiellonian University, 
Cracow, Poland. Voucher specimen KFg/2010016 is de-
posited at the Department of Pharmacognosy, Pharma-
ceutical Faculty, Medical College, Jagiellonian University, 
Cracow, Poland.
 The Lclet 4 compound was isolated according to 
the procedure described in Podolak et al. (2013). Air-
dried plant material (150 g) was extracted with CHCl3 
(400 mL × 3) followed by MeOH with 0.5% pyridine 
(400 mL × 4). The combined extract was concentrated 
in vacuo, dissolved in water and exhaustively eluted with 
n-BuOH. The n-BuOH-soluble fraction was subjected to 
silica gel column chromatography (Merck Kieselgel 60; 
70–230 mesh) using CHCl3/MeOH/H2O 23:12:2 and 
fractions were combined on the basis of TLC. Pooled 
saponin-containing fractions were subjected to repeated 
preparative TLC (commercially precoated silica gel G 
plates; Analtech, 500 microns) using CHCl3/MeOH/
H2O 23:12:2; 8:7:1 as solvents. Bands were removed 
from plates after spraying with water, the silica was ex-
tracted with MeOH and solvent was evaporated in vac-
uo to yield Lclet 4 (86 mg). Its identity was confirmed 
based on chemical and spectral characterization using 
FAB MS and 1D and 2D NMR experiments (Podolak 
et al. 2013) as well as on comparison with literature data 
(Bloor, 1994; Hegde et al., 1995).
Cells and cell culture. Human prostate cancer cell 
line DU-145 and the normal PNT2 prostate cells were 
used in the study. The cells were cultured in standard 
conditions (37°C, 5% CO2) in DMEM- F12 medium 
(DU-145) or in RPMI (PNT2), supplemented with 10% 
FBS.
Lclet 4 and MTX treatment. Cells were seeded into 
the culture dishes at the densities given below and incu-
bated for 24 hours. Afterwards, the culture medium was 
replaced for the new one, supplemented with Lclet 4 or 
MTX alone or with Lclet 4/MTX cocktails. The tested 
concentrations of both compounds ranged from 0.05 
µg/ml to 5 µg/ml for viability tests and from 0.05 to 
0.1µg/ml for other endpoint experiments.
Viability and Lactate Dehydrogenase cytotoxicity 
tests. For viability tests, the cells were seeded into 24-
well plates (Corning) at a density of 1 × 104 cells/cm2, 
were cultivated in the presence of Lclet 4, MTX (0.05 
µg/ml to 5 µg/ml) for 24 hours and their viability de-
termined by the fluoresceine diacetate and ethidium bro-
mide test (Yang et al., 1998). At least 200 cells were ana-
lyzed for each condition.
For Lactate Dehydrogenase (LDH) cytotoxicity tests 
(Clonetech) DU-145 cells were seeded into 96-well plate 
(Corning) at 1 × 104 cells/cm2, incubated for 24 hours 
and treated with the agents for the next 24 hours. The 
plates were then centrifuged at 250 × g for 10 minutes 
and 100 µl of the supernatant was removed carefully 
from each well and transferred into the correspond-
ing wells of an optically clear 96-well flat-bottom plate. 
Next, 100 µl of freshly prepared Reaction Mixture was 
added to each well and incubated in darkness for up 
to 30 minutes at room temperature. Absorbance of the 
samples was measured at 492 nm using a multi-well 
plate reader (TECAN). Cytotoxicity was measured as 
(%) = (Triplicate Absorbance-Low control/High control- 
Low control) × 100. Three independent experiments 
were performed for each condition.
Analysis of apoptosis. DU-145 cells were seeded 
into a Corning flask at a density of 1 × 104 cells/cm2, in-
cubated for 24 hours and treated with the agents for the 
next 24 hours. Then, the cells were washed with PBS 
without Ca2+ and Mg2+ ions, trypsinized, centrifuged and 
counted with a Bürker’s chamber. After washing with 
cold PBS, the cells were resuspended in Binding Buffer 
(Becton Dickinson) at the final concentration of 1 × 106 
cells/ml. Next, 100 µl of the cell suspension (1 × 105 
cells/ml) was transferred to a 5 ml culture tube, followed 
by addition of Annexin V/PI solution (Becton Dickin-
son) and Binding Buffer. Flow cytometric analyses (BD 
LSR II) were performed according to the manufacturer’s 
protocol. 50 000 cells were analyzed in each experiment. 
Three independent experiments were performed for 
each condition.
For the analyses of caspase 3/7 activity DU-145 cells 
were seeded into a 96-well plate at a density of 3 × 103 
cells/cm2. After 24 hours the cells were treated with 
Lclet 4 and MTX alone or with Lclet 4/MTX cocktails 
for the next 24 hours. Caspase-Glo3/7 Reagent (Pro-
mega) was added (100 µl) to each well of a white-walled 
96-well plate, containing 100µl of culture medium. Plates 
were gently agitated using a plate shake 300–500 rpm for 
30 seconds, and incubated at room temperature for 30 
minutes. The sample luminescence was measured in a 
plate-reading luminometer (TECAN) according to manu-
facturer’s instructions. For each condition three experi-
ments were performed.
Time lapse-monitoring of movement of individu-
al cells. Cell movement was observed with an inverted 
Leica DMI6000B microscope with IMC optics, at 37ºC 
and 5% CO2 atmosphere. DU-145 cells were seeded into 
6-well plates at a density of 1 × 104 cells/cm², the me-
dium was replaced with new one containing the agents 
and time-lapse recording of cell movements was imme-
diately performed. The cell trajectories were constructed 
from 88 subsequent centroid positions recorded over 
480 minutes at 15 minute time intervals. They were pre-
sented in circular diagrams with the starting point of 
each trajectory situated at the plot center. The param-
eters characterizing cell locomotion were calculated as 
described previously (Djamgoz et al., 2001; Madeja et al., 
2001). For each data point measured, 50 cells were ana-
lyzed. Pre-apoptotic and apoptotic cells were discriminat-
ed by morphology and their trajectories not considered 
for statistical analysis. Three independent experiments 
were performed for each condition.
Fluorescence staining. DU-145 cells were stained 
with mouse monoclonal antibody against human 
α-tubulin (Sigma-Aldrich) or mouse monoclonal anti-
body against human cytochrome c (Pharmingen) fol-
lowed by Alexa Fluor 488 goat anti-mouse IgG (clone 
A11001, Sigma- Aldrich) and counterstained with Phal-
lodin-TRITC (Sigma-Aldrich). Visualization of specimens 
mounted in polyvinyl alcohol (Mowiol; Sigma-Aldrich) 
was performed with a Leica DMI6000B microscope and 
images were acquired with a DFC360FX CCD camera.
Matrix metalloproteinase expression activity. 
The activities of MMP-2 and MMP-9 were assayed 
by gelatin zymography. Briefly, subconfluent DU-145 
cells were incubated in control serum-free medium, the 
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medium supplemented with Lclet 4 alone, or with the 
Lclet 4/MTX cocktail for 24 hours. Then the super-
natants were collected, mixed with loading buffer and 
subjected to 10% SDS-polyacrylamide gel containing 
0.1% gelatin (Sigma Aldrich, Cat. no G8150). Electro-
phoresis was performed at 70 V for 15 minutes and 
130 V for 120 minutes. Gels were then washed with 
washing buffer (2% Triton X-100) at room tempera-
ture to remove SDS, followed by incubation at 37°C 
in reaction buffer (Tris base, Tris HCl, CaCl2). After 24 
hours the gels were stained with Comassie Blue R-250 
for 1 hour and destained with destaining solution (20% 
methanol, 10% acetic acid, 70% ddH2O). The relative 
optical density (ROD) of the signal bands was estimat-
ed using the ImageJ 1.45s software.
Transmigration experiments. DU-145 cells were 
seeded into chambers containing “naked” microporous 
membranes (Corning, pore diameter: 8 µm, membrane 
diameter: 6.5 mm) at a density of 1 × 104, or membranes 
covered with Matrigel (1:8; Sigma Aldrich) at a den-
sity of 2 × 104 cells/cm2 and allowed to transmigrate in 
the absence or presence of the agents. The cells which 
transmigrated during 24 hours (naked microporous 
membranes) or 72 hours (Matrigel-coated membranes) 
were stained with bis-benzimide (Hoechst 33342-Sigma 
Aldrich) and counted. Three independent experiments 
were performed for each condition.
Statistical methods. Each variable was expressed as 
the mean (± S.E.M.). The statistical significance was de-
termined using the Student’s t-test or the non-parametric 
Mann-Whitney U-test (motility tests), with p < 0.05 con-
sidered to indicate significant differences. For morpho-
logical and fluorescent staining evaluation, at least 20 mi-
croscopic fields of view were analyzed.
RESULTS
Synergistic effects of Lclet 4 and MTX on the viability 
of DU-145 cells
Cell viability assays were first performed to exam-
ine the specificity and synergy of the effects of Lclet 
4 and MTX on the viability of prostate cells. Diac-
etate fluoresceine/ethidium bromide exclusion tests 
demonstrated that neither Lclet 4, MTX nor Lclet 4/
MTX cocktails affected the viability of PNT2 cells, 
when administrated at concentration of up to 1 g/
Figure 1. Additive cytotoxic effect of Lclet 4 and MTX on DU-145 cells.
Neither Lclet 4 nor MTX exerted any effect on the viability of PNT2 (A) and DU-145 cells (B, C) when administered at the concentra-
tions between 0.05 and 0.1 µg/ml. Decreased fraction of viable DU-145 but not PNT2 cells in the presence of the Lclet 4/MTX cocktail 
(0.05–0.1 µg/ml) was paralleled by changes in the morphology of adherent DU-145 cells (D). Bar=20 µm. PNT2 (A) and DU-145 (B, C) 
cells were cultured in medium supplemented with 10% FBS in the presence of Lclet 4 or MTX (in concentrations ranging from 0.05 to 5 
µg/ml) or in the presence of both compounds. After 24 hours of incubation cell viability was determined by the fluoresceine diacetate 
and ethidium bromide test (A–B) and by LDH cytotoxicity test (C). Values represent means ± S.E.M. of the total number of viable cells (%) 
in comparison to vehicle control in three independent experiments (A, B). (*) Statistically significant versus control at p < 0.05.
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ml of each agent (Fig. 1A). In contrast, both agents 
exerted significant cytotoxic effects on DU-145 cells 
at the concentrations between 0.2 and 5 µg/ml (Fig. 
1B). Only minute cytotoxic effects were observed 
when Lclet 4 and MTX were separately administered 
at the concentrations between 0.05 and 0.1 µg/ml. In 
contrast, their combined administration at these con-
centrations significantly attenuated DU-145 cell viabil-
ity (Fig. 1B). For instance, 0.1 µg/ml of Lclet 4 and 
MTX slightly reduced the fraction of fluoresceine+/
EB– cells to 97 and 99%, respectively, whereas the 
percentage of fluoresceine+ cells decreased to 61% in 
the presence of both agents. In order to confirm the 
results of diacetate fluoresceine/ethidium bromide ex-
clusion test, LDH assays were conducted. These tests 
revealed considerably higher cytotoxicity of Lclet 4/
MTX cocktails than separately administrated agents, 
especially at higher concentrations (Fig. 1C). Accord-
ingly, the prolonged incubation of DU-145 cells with 
the cocktail of Lclet 4 and MTX (0.05 µg/ml) resulted 
in the appearance of detached cells, which displayed 
numerous blebs reminiscent of apoptotic bodies (Fig. 
1D). No such effect could be observed in the pres-
ence of each agent when administered alone. These 
data indicate that the combination of Lclet 4 and 
MTX applied at non-cytotoxic concentrations effec-
tively induces an apoptotic response of DU-145 cells.
Figure 2. Lclet 4 and MTX induced apoptotic response in DU-145 cells is accompanied by up-regulation of caspase 3/7 and release 
of cytochrome c from mitochondria.
DU-145 cells were cultured in medium supplemented with 10% FBS in the presence of Lclet 4 (0.05 or 0.1 µg/ml) or MTX (0.05 or 0.1 µg/
ml), or in the presence of Lclet 4/MTX cocktails. After 24 hours the cells were stained with Annexin V/PI for FACSs analyses. Dot-plots of 
Annexin V/ PI (FITC-A/PE-Texas Red A) — stained cells (A) were quantified and the results presented as percent of apoptotic (early-apop-
totic (EA) + late-apoptotic (LA)) cells (B). Activity of caspase 3/7 was determined using luminescence method (C). Values represent means 
± S.E.M. in arbitrary units (relative luminescence units — RLU) of three independent experiments; (*) statistically significant versus control 
at p < 0.05 (B) and p < 0.001 (C). Intracellular localization of cytochrome c was visualized by immunofluorescence staining performed 24 
hours after administration of the agents (D). Bar=20 µm.
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Lclet 4 and MTX synergistically induce apoptosis in DU-
145 cells
Flow cytometry analyses of Annexin V/PI cells were 
further performed to confirm the apoptotic response of 
DU-145 cells evoked by combined Lclet 4/MTX treat-
ment. When administered alone at the concentrations 
of 0.05 and 0.1 µg/ml, both agents induced only min-
ute apoptotic response of DU-145 cells, whereas their 
combination increased the fraction of Annexin V+ cells 
up to 25% (0.05 µg/ml) and 75% (0.1 µg/ml; Fig. 2A 
summarized in B). The analyses of caspase 3/7 activ-
ity in treated cells (Fig. 2C) confirmed the synergistic 
character of pro-apoptotic effects of Lclet 4 and MTX 
in DU-145 populations. A significantly increased activity 
of both enzymes in DU-145 cells treated with the Lclet 
4/MTX cocktails was observed. Accordingly, the syner-
gistic pro-apoptotic effect of both agents was confirmed 
by the analyses of cytochrome c release from DU-145 
mitochondria, which was observed in the Lclet 4/MTX 
cocktail-treated cells (Fig. 2D).
Synergistic effect of Lclet 4/MTX cocktails on the 
invasive potential of DU-145 cells
We further analyzed the effect of Lclet 4/MTX 
cocktails on DU-145 motility on planar substrata. Both 
agents significantly inhibited non-apoptotic DU-145 
translocations when administered alone at the concentra-
tions of 0.05 and 0.1 µg/ml. The magnitude of this at-
tenuation was the highest in the presence of the Lclet 
4/MTX cocktail (Fig. 3A, Table 1). The effects of Lclet 
4/MTX on DU-145 motility were paralleled by chang-
es in cytoskeleton architecture, i.e. partial disintegration 
Figure 3. Attenuating effect of Lclet 4/MTX cocktails on the motility and MMP expression in DU-145 cells
DU-145 cells were cultured in medium supplemented with 10% FBS in the presence of Lclet 4 (0.05 µg/ml), MTX (0.05 µg/ml) or Lclet 
4/MTX cocktails. Time lapse analyses of single DU-145 cell movement were performed after 24 hours of incubation (A), paralleled by 
immunocytochemical analysis of actin cytoskeleton (B) and microtubule organization (C). Bar=20 µm. Transmigration of DU-145 cells 
through “naked” (D) and matrigel-coated microporous membranes (E) was analyzed, 24 hours (D) and 72 hours (E) after cell seeding 
in the presence of agents. Matrix metalloproteinase (MMP-2 and MMP-9) secretion was analyzed by gelatin zymography after 24 hours 
of incubation with the tested compounds. (F). Values represent means ± S.E.M. in arbitrary units (relative optical density  ROD) after 24 
hours of incubation.
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of microfilament bundles (Fig. 3B) and microtubules 
(Fig. 3C), most prominent in cells treated with the Lclet 
4/MTX cocktail. Importantly, in contrast to apoptosis 
induction, all the analyzed cells responded to the Lclet 
4/MTX cocktail with an inhibition of motility, whereas 
apoptosis was observed only in a fraction of DU-145 
cells. To directly address the anti-invasive effects of both 
agents, we further examined the transmembrane migra-
tion efficiency of DU-145 cells (Fig. 3D, E). A relatively 
strong inhibition of DU-145 transmigration through “na-
ked” microporous membranes was seen in the presence 
of the Lclet 4/MTX cocktail (Fig 3D). It was paralleled 
by a synergistic inhibitory effect of both agents on the 
transmigration of DU-145 cells through Matrigel-coated 
microporous filters (Fig 3E). Notably, a distinct synergis-
tic effect of Lclet 4 and MTX on the activity of metallo-
proteinases was also observed. No significant differences 
in MMP-2/MMP-9 activity were observed in DU-145 
populations treated with Lclet 4 or MTX alone for 24 
hours (Fig. 3F). In contrast, a considerable inhibition of 
their activity could be seen in DU-145 populations treat-
ed with the Lclet 4/MTX cocktail. These data indicate 
that the cocktail of both agents administered individu-
ally at non- cytotoxic concentrations may interfere with 
prostate cancer invasion through the combined effect on 
cell motility and the ability of prostate cancer cells to de-
grade local tissues.
DISCUSSION
Current strategies of prostate cancer treatment should 
not only keep in focus prolonged longevity but also 
the life quality of the affected patients. The combined 
therapy based on the application of bioactive plant 
compounds, such as saponins, with well known chemo-
therapeutic agents may help to attenuate prostate cancer 
progression without evoking undesired adverse effects. 
Combinations of therapeutic drugs with different modes 
of anti-cancer activity can allow for lowering their con-
centrations and for reduction of systemic toxicity (Beren-
baum, 1989; Greco et al., 1995). Here, we demonstrated 
that the administration of Lysymachia sp. saponin — Lclet 
4, augments the cytostatic and anti-invasive potential of 
mitoxantrone - an agent commonly used in prostate can-
cer therapy. These data indicate that Lclet 4/MTX-based 
combined therapy may allow for decreasing the effective 
MTX concentrations, thus reducing its adverse effects.
Application of saponins has previously been proposed 
for combined therapy of a range of cancers, including 
drug resistant colon cancer and leukemia (Li et al., 2011; 
Wink et al., 2012). For instance, digitonin (saponin iso-
lated from Digitalis sp.) synergistically enhanced the cyto-
toxicity towards MCF-7 and Caco-2 cells, when admin-
istered in combination with thymol, EGCC or glaucin 
(Eid et al., 2012). Similarly, Panax notoginseng saponins 
enhanced the cytotoxicity of cisplatin (Yu et al., 2012). 
Our data showed that the cytotoxic and pro-apoptotic 
activity of Lclet 4/MTX cocktails was considerably high-
er than that of each agent administered alone. Compara-
tive analyses of prostate cancer and normal cell reactions 
to Lclet 4/MTX cocktails showed their selective cyto-
static and pro-apoptotic effects on cancer cells and the 
lack of adverse
effects on normal cell growth. Previously, green tea 
polyphenols were shown to enhance the growth inhibi-
tory effect of cyclooxygenase-2 inhibitor on human pros-
tate cancer cells in vitro an in vivo (Adhami et al., 2007). 
Similarly, combined application of resveratrol or propolis 
with vinorelbine reinforced DU-145 cell growth inhibi-
tion (Scifo et al., 2006). Our findings demonstrate the 
potential of the Lclet 4/MTX-based therapeutic regimen 
for systemically neutral, palliative prostate cancer treat-
ment.
Proapoptotic activity is a major goal in clinical can-
cer research aimed at identifying compounds that would 
selectively affect cancer cells (Hickman, 2002; Wang et 
al., 2007; Fuchs et al., 2009; Kim et al., 2010; Chen et al., 
2012). In only a few reports was saponin activity con-
sidered in terms of inhibition of cancer progression. For 
instance, ginsenoside Rb2 was shown to inhibit tumor 
associated angiogenesis after intravenous inoculation of 
B16-BL6 melanoma cells and to suppress lung metas-
tases (Mohizuki et al., 1995), whereas ginsenoside Rg3 
Table 1. Effect of Lclet 4 and MTX on the motility of DU-145 cells
DU-145 cells were cultured in medium supplemented with 10% FBS in the presence of Lclet 4 (0.05 µg/ml), mitoxantrone (0.05 µg/ml) 
alone or in the presence of both compounds for 24 hours. Results statistically significant vs Lclet 4 (*) and vs mitoxantrone (#); p < 0.05
Vol. 60       337Lclet 4 enhances the effects of mitoxantrone on prostate cancer cells
augmented anti-angiogenic effects of gemcitabine (Liu et 
al., 2009). Our report is perhaps the first to demonstrate 
the synergy of the anti-invasive activities of saponins and 
cytostatic drugs on prostate cancer cells. Not surpris-
ingly, the pronounced inhibition of prostate cancer cell 
movement in the presence of the Lclet 4/MTX cocktail 
was accompanied by changes in cytoskeleton architecture 
of DU-145 cells. Together with their influence on DU-
145 transmigration and metalloproteinase activity, these 
changes comprehensively illustrate the multifaceted ac-
tion of Lclet 4 and MTX on DU-145 invasiveness. It is 
premature to speculate whether cytoskeletal rearrange-
ments result from the direct effect of both agents on 
cytoskeletal proteins. However, the inhibition of MMP-2 
and MMP-9 activity was previously found to suppress 
the metastatic potential of prostate cancer cells (Itoh & 
Nagase, 2002; Chien et al., 2010). Conceivably, synergis-
tic effects of Lclet 4 and MTX on MMP-2 and MMP-
9 activity predominantly account for the attenuation of 
DU-145 invasive potential.
A strong pro-apoptotic and anti-invasive activity of 
Lclet 4/MTX cocktails at concentrations at which the 
individual components were non-toxic, demonstrates that 
such a combined treatment can be advantageous in ma-
lignancies that are irresponsive to either treatment alone. 
Furthermore, synergistic activation of the caspase3/7 
system and the inhibition of MMP-2 and MMP-9 activ-
ity by the Lclet 4/MTX cocktail was accompanied by its 
synergetic effects on cell motility. Notably, inhibition of 
motility was observed in virtually all treated cells, regard-
less of their further apoptosis-related fate. This indicates 
that the pro-apoptotic effects of the Lclet 4/MTX cock-
tail are independent of its anti-invasive activity on DU-
145 cells. The synergy of Lclet 4 and MTX effects may 
rely on their independent interference with intracellular 
signalling systems determining cancer cell viability and 
invasiveness. Importantly, neither Lclet 4 nor MTX af-
fected MMP-2/9 and caspase 3/7 function in DU-145 
cells when administered alone. Accordingly, Lclet 4 may 
help to amplify weak signals produced by MTX and/or 
circumvent the drug resistance. Saponosides were shown 
to modulate multiple drug resistance (MDR) in tumor 
cells, thus Lclet 4 can sensitize DU-145 cells to MTX in 
this way (Wink et al., 2012). In general, the elucidation 
of the structure-activity relationship of different saponins 
in combination with conventional drugs is much more 
challenging than the studies of saponins alone.
When extrapolated to in vivo situation, our observa-
tions suggest that Lclet 4/MTX cocktails may, through 
the converging effects, interfere with the efficiency of 
prostate cancer metastatic cascade. Combined, although 
independent, pro-apoptotic and anti- invasive effects ac-
count for their activity. Whereas the mechanistic aspects 
of this convergence remain elusive, our observations ex-
pand the knowledge about a wide range of saponin ac-
tivities. Further detailed studies on this topic may result 
in elaboration of efficient saponin-based tumor therapies 
in the future.
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